Fifth Third Bancorp (FITB): what the price requires

At today's price, Fifth Third Bancorp (FITB) is priced for 15.8% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-17 · Source: https://boothcheck.com/report/FITB

Headline

FieldValue
TickerFITB
CompanyFifth Third Bancorp
Current price$57.11/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Price-to-book1.62x
Return on equity now11.9%

The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The price sits beyond a 13% return on equity sustained for 40 years and is not resolvable as a sustainable-ROE point. The rarity read below is the honest signal.

Solve inputs: computed at a 11.3% cost of equity; ROE searched up to the 13% ROE ceiling.

Reconcile: at the x-ray's 9.3% required return this reads ~12.5%; the models below use their own rates.

How unusual the bet is: extreme

ReferenceValue
vs own history+1.63σ
cohort percentile (of 119 peers)71
sustained it ~10 years at this level57%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.02x3expensive
Earnings1.78x1expensive
Relative1.41x1expensive
Growth1.17x3expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$13.454.25xyesTBVPS $27.59 × 0.49x (ROE (TTM) 6.4% / CoE 9.3%, g=4.1% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 1.69% allowance/loans → ×0.97)
Relative ValuationRelative$40.381.41xyesP/E 13.55x (blended: static sector reference 10x + trailing (TTM) 22x), scenarios: 11.1x / 13.6x / 16.0x (bear / base = reference held flat / bull), EV/EBITDA N/Ax
Simple DDMGrowth$54.771.04xyesDPS $1.48, g=6.4% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$15.803.61xyesStage 1: -8% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$28.282.02xyesBV/sh $41.08, ROE (TTM) 6.4%, ke 9.3%
Two-Stage Excess ReturnAsset$23.052.48xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$49.011.17xyesRev $6.5B, growth 14% (input: historical growth; tapered), Terminal P/S: 6.0x / 7.3x / 8.6x (bear / base = today's held flat / bull, cap 12x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$52.391.09xyes√(22.5 × EPS $2.97 × BVPS $41.08) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$2.4922.94xyesEPS $2.97 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative——no—
Earnings YieldEarnings$32.111.78xyesEPS $2.97 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (dilution)4.5%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

The valuation methods scatter wildly here, from about $13 to $55, and the reason is a corrupted input: trailing return on equity reads just 6.4% because the Comerica merger that closed in February loaded the quarter with $567 million of one-time charges.

Strip those charges and the picture changes. The dividend-discount method lands at $55 and the future-market-cap method at $45, both near the price, while the bank-model floor at $13 is mechanically depressed by the temporary earnings hit.

The whole thesis is the merger. Fifth Third is now the ninth-largest U.S. bank with $290 billion in assets, targeting $850 million in pre-tax synergies by year-end. The dividend yields about 3.6%.

Bull Case

Traditional bank valuation models are misreading Fifth Third right now, and the reason is mechanical. But the 6.4% is an artifact. The Comerica merger closed on February 1, 2026, and Q1 absorbed $567 million of after-tax merger and one-time charges, a $0.68-per-share hit that pushed EPS down to $0.15 from a normalized level several times higher. A model that capitalizes one quarter of merger-suppressed earnings as if they were permanent is measuring the integration cost, not the franchise.

What the franchise actually became is a much larger bank. Fifth Third is now the ninth-largest in the United States with $290 billion in assets, and the merger drove fully taxable-equivalent net interest income up 34% year over year while the net interest margin expanded to 3.30%. The combined company is targeting $850 million in pre-tax run-rate synergies by the end of 2026, roughly 35% of Comerica's expense base, and net interest income is driven by the level and mix of rates on the enlarged balance sheet (accession 0000035527-26-000124). As those charges roll off and the synergies land, the return on equity should normalize well above the trailing figure, and the dividend-discount method, which looks through to a sustainable payout, already lands at $55, essentially at the price.

The forward-looking methods and the sell-side agree the static read is wrong. The future-market-cap method lands at $45, the relative-valuation method at $39, and the Graham number at $52 (June 27, 2026), while analysts have been raising targets into a $50-to-$67 range with a Buy consensus, citing expense savings and margin protection from the merger. The dividend yields about 3.6%, above the bank-industry average. For a buyer who can see past the integration quarter to the normalized earnings power of a top-ten bank capturing real synergies, the depressed model is the opportunity.

Bear Case

The honest way to frame the risk is the model disagreement itself, because the methods cannot agree on what this bank is worth and the conservative ones deserve respect. The bank-specific tangible-book model says $13, the two-stage excess-return method $23, the simple excess-return method $28, the relative method $39, and the dividend-discount method $55. That is a four-fold spread, and it exists because the central input, return on equity, is unreliable: at the trailing 6.4% the bank is earning well below its 9.3% cost of capital, and a bank that does not out-earn its cost of capital deserves to trade below book, not at a premium. The bull case requires the optimistic methods to be right, and the optimistic methods all assume a normalization that has not yet shown up in the numbers.

The normalization is a bet on flawless merger execution, which is the hardest thing in banking. The $850 million synergy target rests on cutting 35% of Comerica's expense base while retaining its customers and bankers, and large bank integrations routinely lose deposits, relationship managers, and commercial clients in the transition. If even part of the synergy target slips, or if deposit attrition runs hot, the normalized return on equity lands below what the price assumes, and the conservative methods that say $13 to $28 become the relevant ones. The merger also raised the share count through stock issuance, diluting per-share metrics, and the trailing return is genuinely depressed, not merely optically so.

The macro backdrop adds a credit overlay. A bank that just doubled its commercial-and-industrial and commercial-real-estate exposure through Comerica is more sensitive to a downturn, and the filing flags the unpredictable, large-scale events that can impair borrowers and disrupt operations (accession 0000035527-26-000124). With a high beta and an allowance already at 1.69% of loans, a credit cycle would hit the very earnings recovery the price is counting on. The stock looks cheap only on the methods that assume the merger works perfectly; on the methods that take the current returns at face value, it is expensive. That disagreement is the risk, and it resolves only when the post-merger earnings prove which set of methods was right.

Valuation

Fifth Third is a financial, so the read is the return on equity against its cost, and that input is the whole problem this quarter. Trailing return on equity is just 6.4% against a 9.3% cost of capital, but the figure is distorted by $567 million of one-time merger charges, so it understates the normalized earnings power of the combined bank. The bank-specific tangible-book model, which capitalizes that depressed return, lands at $13, far below the $53 price. That is the mechanical floor, and it should be read as merger-suppressed rather than as the true value.

The model X-ray scatters accordingly. The dividend-discount method, looking through to a sustainable payout, lands at $55, the future-market-cap method at $45, the relative method at $39, the Graham number at $52, the earnings-yield method at $32, and the excess-return methods between $23 and $28. The reported band runs from about $28 at the low end to $39 at the base and $44 at the high, with reliability tagged as ok, and the price sits above that high mark.

The honest summary is that the methods cannot price this bank cleanly until the merger charges clear and the synergies prove out. On a normalized basis, the sell-side range of $50 to $67 and the dividend-discount read near $55 suggest the price is reasonable to cheap; on the trailing, charge-laden basis, the conservative methods say it is expensive. The deciding variable is the post-merger return on equity, and the next few quarters of charge-free results are what will resolve the disagreement.

Catalysts

The defining event has already happened: the Comerica merger closed on February 1, 2026, creating the ninth-largest U.S. bank with $290 billion in assets. Q1 2026 was the first combined quarter and it was messy by design, with EPS of $0.15 after $567 million of after-tax merger and one-time charges, net income to common of $128 million, fully taxable-equivalent net interest income up 34% year over year, and a net interest margin of 3.30%. The next few prints, as charges roll off, are the catalysts that will show the normalized earnings power.

Synergy execution is the multi-quarter swing factor. Management is targeting $850 million in pre-tax run-rate synergies by the end of 2026, roughly 35% of Comerica's expense base, and confidence in hitting that number is the lever analysts cite for margin protection and upside. Watching expense control, deposit retention, and banker attrition through the integration is the cleanest read on whether the bull or bear methods prove right.

Sentiment has turned constructive. The consensus is a Buy with an average target near $54 and a range from $50 to $67, and recent moves include Morgan Stanley to $67, UBS upgrading to Buy at $57, and Barclays to $63 at Overweight, all citing merger synergies and credit trends. The dividend was set at $0.40 for the second quarter, a yield near 3.6%, which supports the wait while the integration plays out.

Sources: stocktitan.net (Q1 2026 results), grafa.com (Comerica merger impact), finance.yahoo.com (analyst target revisions), marketbeat.com (FITB forecast).

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive FITB report on boothcheck